6:16 AM ET
10-Q
Financial Results
Cocrystal Pharma Q3 2026 Results: Net Loss of $3.44M, Loss Widens
Cocrystal Pharma reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to $6.4 million in the prior year, driven by increased research and development expenses. The company raised substantial doubt about its ability to continue as a going concern, noting that its $4.9 million in cash and restricted cash is insufficient to fund operations for the next 12 months.
- Key figure
- Net loss $3.44M